Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 31

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 31
---
centive Plan (the “Scilex Pharma 2017 Plan”) with a weighted average exercise price of $26.95 per share; |

| • |     | 432,087 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock            
 Option Plan of Scilex, Inc. (the “2019 Stock Option Plan”) with a weighted average exercise price of $60.55 per share; |

21

| • |     | 571,738 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex Holding                
 Company 2022 Equity Incentive Plan (the “Equity Incentive Plan”), with a weighted average exercise price of $200.55 per share; |

| • |     | up to 494,662 shares of Common Stock available for future issuance under the Equity Incentive Plan; |

| • |     | up to 118,350 shares of Common Stock available for future issuance under the Scilex Holding Company 2022 Employee 
 Stock Purchase Plan (the “ESPP”);                                                                                 |

| • |     | up to 40,000 shares of Common Stock available for future issuance under the Scilex Holding Company 2023 
 Inducement Plan (the “Inducement Plan”);                                                                |

| • |     | up to 6,958,309 SPAC Warrants (on a pre-Reverse Stock Split basis), which                                                                                                        
 are currently exercisable for an aggregate of up to 198,810 shares (on a post-Reverse Stock Split basis) of Common Stock, with an exercise price of $402.50 per whole share; and |

| • |     | 6,500,000 shares of Common Stock issuable upon the exercise of the Penny Warrants, with an exercise price of 
 $0.01 per share.                                                                                             |

22

RISK FACTORS Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled “Cautionary Note Regarding Forward-Looking Statements”. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described